Physician profile
Rajnikanth Narayanan
NPI 1780713032
$3,338.34
in general payments reported to CMS, 2019-2025
25 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $370 · 2023: $485 · 2024: $1,203 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276 · Consulting Fee: $225 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,275.60 |
| Consulting Fee | $225.00 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $385.78 | 2022-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $286.43 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $282.35 | 2021-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $240.28 | 2021-2023 | Krystexxa |
| Ardelyx, INC. | $213.59 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $182.98 | 2021-2024 | Jynarque |
| Novo Nordisk INC | $178.95 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $173.60 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $166.25 | 2022-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $155.18 | 2021-2025 | |
| Daiichi Sankyo INC. | $145.57 | 2021-2025 | Injectafer |
| Akebia Therapeutics INC | $138.36 | 2021-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.22 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $131.00 | 2021-2023 | Korsuva, Veltassa |
| Opko Pharmaceuticals, LLC | $109.83 | 2021-2024 | Rayaldee |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.80 | 2021-2025 | |
| Nxstage Medical, INC. | $63.53 | 2021-2024 | Liberty Select Cycler, Nxstage System One |
| Alexion Pharmaceuticals, INC. | $55.76 | 2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $43.54 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $36.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.98 | 2023 | Gattex |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.21 | 2024 | Jynarque |
| Ani Pharmaceuticals, INC. | $25.12 | 2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $24.23 | 2024 | |
| Boston Scientific Corporation | $19.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajnikanth Narayanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.